Related Experiment Videos
A p105-based inhibitor broadly represses NF-kappa B activities
Dexue Fu1, Minae Kobayashi, Li Lin
1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
The Journal of Biological Chemistry
|January 3, 2004
Summary
A novel p105-based NF-kappaB super repressor (p105(sr)) effectively inhibits all NF-kappaB activities, including atypical complexes. This broad inhibition enhances cancer cell killing, offering new therapeutic potential.
Area of Science:
- Molecular Biology
- Cellular Biology
- Immunology
Background:
- Nuclear Factor kappa B (NF-kappaB) transcription factors regulate gene expression and are implicated in various pathological conditions.
- Existing NF-kappaB inhibitors, like IkappaBalpha-based repressors, have limitations in targeting all NF-kappaB/Rel protein complexes.
- Atypical NF-kappaB complexes (e.g., p50/p52 homodimers, RelB heterodimers) contribute to disease and are not fully inhibited by current methods.
Purpose of the Study:
- To design and validate a novel p105-based NF-kappaB super repressor (p105(sr)) with broader inhibitory activity.
- To assess the efficacy of p105(sr) in inhibiting all NF-kappaB species, including atypical complexes.
- To evaluate the potential of p105(sr) in enhancing cancer cell apoptosis, particularly in conditions with elevated p50 homodimer activity.
Main Methods:
- Generation and characterization of a modified p105 protein engineered as a super repressor (p105(sr)).
- Assessment of p105(sr)'s inhibitory effects on various NF-kappaB/Rel protein complexes, including homodimers and heterodimers.
- Evaluation of p105(sr)'s impact on tumor necrosis factor alpha-mediated apoptosis in MT1/2 skin papilloma cells.
Main Results:
- The developed p105(sr) effectively inhibits all NF-kappaB activities without generating p50 and undergoing signal-induced degradation.
- p105(sr) demonstrates broader inhibitory range compared to IkappaBalpha-based repressors, targeting atypical NF-kappaB complexes.
- p105(sr) significantly enhances tumor necrosis factor alpha-induced killing of skin papilloma cells with elevated p50 homodimer activity.
Conclusions:
- p105(sr) represents a potent and broadly acting NF-kappaB super repressor.
- This novel inhibitor holds promise for therapeutic applications in diseases driven by dominant or multiple activated NF-kappaB species.
- p105(sr) offers a potential strategy for enhancing cancer therapy, especially in tumors with specific NF-kappaB activation profiles.